| pubmed-article:16978222 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0026986 | lld:lifeskim |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0075616 | lld:lifeskim |
| pubmed-article:16978222 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16978222 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16978222 | pubmed:dateCreated | 2006-10-11 | lld:pubmed |
| pubmed-article:16978222 | pubmed:abstractText | The influence of Exisulind on the viability and apoptosis of CD34(+) stem cells from patients with advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)/MDS was investigated. In eight out of 10 patient samples Exisulind reduced the fraction of viable cells by inducing apoptosis. We found evidence that Exisulind-mediated apoptosis depends on c-Jun NH(2)-terminal kinase (JNK) activation. Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS. | lld:pubmed |
| pubmed-article:16978222 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16978222 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16978222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16978222 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16978222 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16978222 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:HaasRainerR | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:LibermannTowi... | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:AivadoManuelM | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:JägerMarkusM | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:KobbeGuidoG | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:ZerbiniLuiz... | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:KnippSabineS | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:CzibereAkosA | lld:pubmed |
| pubmed-article:16978222 | pubmed:author | pubmed-author:PrallWolf CWC | lld:pubmed |
| pubmed-article:16978222 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16978222 | pubmed:volume | 135 | lld:pubmed |
| pubmed-article:16978222 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16978222 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16978222 | pubmed:pagination | 355-7 | lld:pubmed |
| pubmed-article:16978222 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:meshHeading | pubmed-meshheading:16978222... | lld:pubmed |
| pubmed-article:16978222 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16978222 | pubmed:articleTitle | Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. | lld:pubmed |
| pubmed-article:16978222 | pubmed:affiliation | Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine-University, Düsseldorf, Germany. aczibere@bidmc.harvard.edu | lld:pubmed |
| pubmed-article:16978222 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16978222 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
